1. Hematology/Oncology
  2. Learn Genomics
  3. Lung Cancer: Assessment, Treatment
Lung Cancer: Assessment, Treatment
Lung Cancer: Assessment, Treatment
0%
Your Module Progress

References

  1. Karachaliou N, Fernandez-Bruno M, Paulina Bracht JW, et al: EGFR first- and second-generation TKIs—there is still place for them in EGFR -mutant NSCLC patients. Translational Cancer Research:S23-S47, 2018
  2. Blackhall F, Barlesi F, Hochmair M, et al: Oncogenic Drivers in Advanced NSCLC: Navigating an Evolving Landscape to Optimise Patient Outcomes, European Society for Medical Oncology (ESMO). Virtual Congress, EMJ Oncol, 2020, pp 33-42
  3. Loh Z, Mitchell P, John T, et al: RET-rearranged non-small-cell lung cancer and therapeutic implications. Intern Med J 49:1541-1545, 2019
  4. Marmarelis ME, Langer CJ: Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations. Clin Lung Cancer 21:395-406, 2020
  5. Guo Y, Cao R, Zhang X, et al: Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer. Onco Targets Ther 12:10343-10360, 2019
  6. Du X, Shao Y, Qin HF, et al: ALK-rearrangement in non-small-cell lung cancer (NSCLC). Thorac Cancer 9:423-430, 2018
  7. Yu HA, Planchard D, Lovly CM: Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book 38:726-739, 2018
  8. Roviello G, D'Angelo A, Sirico M, et al: Advances in anti-BRAF therapies for lung cancer. Invest New Drugs 39:879-890, 2021
  9. Ou SI, Zhu VW, Nagasaka M: Catalog of 5' Fusion Partners in ALK-positive NSCLC Circa 2020. JTO Clin Res Rep 1:100015, 2020
  10. Adderley H, Blackhall FH, Lindsay CR: KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition. EBioMedicine 41:711-716, 2019
  11. Salgia R, Pharaon R, Mambetsariev I, et al: The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Rep Med 2:100186, 2021
  12. Zhao J, Xia Y: Targeting HER2 Alterations in Non–Small-Cell Lung Cancer: A Comprehensive Review.411-425, 2020
  13. Harada G, Santini FC, Wilhelm C, et al: NTRK fusions in lung cancer: From biology to therapy. Lung Cancer 161:108-113, 2021
  14. Recondo G, Bahcall M, Spurr LF, et al: Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC. Clin Cancer Res 26:2615-2625, 2020
  15. Drusbosky LM, Rodriguez E, Dawar R, et al: Therapeutic strategies in RET gene rearranged non-small cell lung cancer. J Hematol Oncol 14:50, 2021
  16. Riudavets M, Sullivan I, Abdayem P, et al: Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. ESMO Open 6:100260, 2021
  17. Reck M, Carbone DP, Garassino M, et al: Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol 32:1101-1110, 2021
  18. Vyse S, Huang PH: Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther 4:5, 2019
  19. Xu H, Yang G, Li W, et al: EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes. Front Oncol 11:713483, 2021
  20. Miles B, Mackey JD: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Lung Cancer: History, Epidemiology, and Market Outlook. Cureus 13:e13470, 2021
  21. US Food and Drug Administration: FDA approves dacomitinib for metastatic non-small cell lung cancer,  (ed 12/14/2018). US Food and Drug Administration, FDA, 2018
  22. US Food and Drug Administration: FDA approves osimertinib for first-line treatment of metastatic NSCLC with most common EGFR mutations, in Administration UFaD (ed):  (ed 04/19/2018), US Food and Drug Administration, 2018
  23. Lindeman NI, Cagle PT, Aisner DL, et al: Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med 142:321-346, 2018
  24. Chan BA, Hughes BG: Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res 4:36-54, 2015
  25. Harrison PT, Vyse S, Huang PH: Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol 61:167-179, 2020
  26. Lin JJ, Shaw AT: Recent Advances in Targeting ROS1 in Lung Cancer. J Thorac Oncol 12:1611-1625, 2017
  27. Russo A, Lopes AR, Scilla K, et al: NTRK and NRG1 gene fusions in advanced non-small cell lung cancer (NSCLC). Precis Cancer Med 3, 2020
 Previous Section Return to Home 
Expert Perspectives